Aratana Therapeutics (PETX) Given Media Impact Rating of 0.18
News headlines about Aratana Therapeutics (NASDAQ:PETX) have trended somewhat positive on Saturday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aratana Therapeutics earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 47.3225044227132 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
PETX has been the topic of a number of research reports. ValuEngine downgraded shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. BidaskClub downgraded shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Zacks Investment Research upgraded shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a report on Tuesday, July 4th. Jefferies Group LLC set a $8.00 target price on shares of Aratana Therapeutics and gave the stock a “buy” rating in a report on Friday, August 4th. Finally, Lake Street Capital reduced their target price on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 25th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $8.25.
Aratana Therapeutics (NASDAQ:PETX) opened at 6.37 on Friday. The stock’s market capitalization is $273.92 million. The company’s 50 day moving average is $5.93 and its 200-day moving average is $6.18. Aratana Therapeutics has a 1-year low of $4.97 and a 1-year high of $9.90.
Aratana Therapeutics (NASDAQ:PETX) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.03. The business had revenue of $5.16 million during the quarter, compared to analysts’ expectations of $4.50 million. Aratana Therapeutics had a negative net margin of 642.93% and a negative return on equity of 51.21%. The company’s quarterly revenue was down 86.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.61 earnings per share. Analysts forecast that Aratana Therapeutics will post ($1.09) earnings per share for the current fiscal year.
In related news, insider Ernst Heinen sold 10,000 shares of the firm’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $6.25, for a total transaction of $62,500.00. Following the completion of the sale, the insider now directly owns 130,994 shares in the company, valued at $818,712.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Peter Steven St sold 50,000 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $6.24, for a total transaction of $312,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 70,000 shares of company stock valued at $435,600. 5.20% of the stock is owned by company insiders.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.